Analyst Yaron Werber of TD Cowen reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $59.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yaron Werber has given his Buy rating due to a combination of factors surrounding Ionis Pharmaceuticals’ promising financial outlook and strategic advancements. The company is preparing for the commercialization of Tryngolza for familial chylomicronemia syndrome and anticipates the approval of donidalorsen for hereditary angioedema by August 2025. These developments are expected to significantly boost revenue, with guidance set at over $600 million for fiscal year 2025.
Additionally, Ionis Pharmaceuticals has demonstrated strong performance in its royalty streams and product launches. The Q4 royalties from Spinraza surpassed consensus expectations, indicating robust market presence, while the launch of Wainua shows promising traction in the transthyretin amyloidosis with polyneuropathy market. Furthermore, the company’s pipeline is rich with Phase 3 data expected in the coming years, supporting confidence in future growth. These strategic and financial indicators collectively underpin Werber’s optimistic assessment of Ionis Pharmaceuticals’ stock.
In another report released today, Needham also maintained a Buy rating on the stock with a $60.00 price target.